Klotho Neurosciences develops disease modifying therapies for age-related cognitive and neurodegenerative disorders and cancer.
Klotho Neurosciences has raised $11.0M in total funding. The most recent round was Post-IPO Equity. The last funding was announced in June 2025.
Klotho Neurosciences's investors include Gaensel Energy Group.
Klotho Neurosciences is headquartered in Omaha, United States.
Klotho Neurosciences develops disease modifying therapies for age-related cognitive and neurodegenerative disorders and cancer.
Klotho Neurosciences is at the Post-IPO Equity stage.
Free to use in articles, research, and reference works. Stable URL — will not change. Data on this page last updated .
"Klotho Neurosciences — Funding & Investors." VCBacked, June 16, 2025, https://www.vcbacked.co/company/klotho-neurosciences. Accessed August 14, 2026.
VCBacked. (2025). Klotho Neurosciences — Funding & Investors. Retrieved August 14, 2026, from https://www.vcbacked.co/company/klotho-neurosciences
{{cite web |title=Klotho Neurosciences — Funding & Investors |url=https://www.vcbacked.co/company/klotho-neurosciences |website=VCBacked |access-date=August 14, 2026}}Profile data sourced and verified per the VCbacked methodology · Last funding round dated